Achillion Pharmaceuticals (Achillion Pharmaceuticals) Price-to-Operating-Cash-Flow : (As of Apr. 26, 2024)

View and export this data going back to 2006. Start your Free Trial

What is Achillion Pharmaceuticals Price-to-Operating-Cash-Flow?

As of today (2024-04-26), Achillion Pharmaceuticals's share price is $6.76. Achillion Pharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2019 was $-0.43. Hence, Achillion Pharmaceuticals's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Achillion Pharmaceuticals's Price-to-Operating-Cash-Flow or its related term are showing as below:

ACHN's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 24.725
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Achillion Pharmaceuticals's Cash Flow from Operations per share for the three months ended in Sep. 2019 was $-0.12. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2019 was $-0.43.

Achillion Pharmaceuticals Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Achillion Pharmaceuticals's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achillion Pharmaceuticals Price-to-Operating-Cash-Flow Chart

Achillion Pharmaceuticals Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

245.23

Achillion Pharmaceuticals Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Achillion Pharmaceuticals's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Achillion Pharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Achillion Pharmaceuticals's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Achillion Pharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Achillion Pharmaceuticals's Price-to-Operating-Cash-Flow falls into.

Achillion Pharmaceuticals Price-to-Operating-Cash-Flow Calculation

Achillion Pharmaceuticals's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	6.76	/	-0.431
	=

Achillion Pharmaceuticals's Share Price of today is $6.76.
Achillion Pharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.43.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Achillion Pharmaceuticals Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Achillion Pharmaceuticals's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Achillion Pharmaceuticals (Achillion Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achillion Pharmaceuticals Inc (NAS:ACHN) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

N/A

Address

300 George Street, New Haven, CT, USA, 06511

Website

http://www.achillion.com

Achillion Pharmaceuticals Inc is a biotechnology company that seeks to discover and commercialize treatments for rare diseases. The company is engaged solely in the discovery and development of innovative small-molecule drug therapies for infectious diseases and immune system disorders. Achillion specializes in structural biology, medicinal chemistry, and antimicrobial discovery research. The company generates revenue from product sales, regulatory and commercialization milestones, and royalties. Achillion also uses collaborative and licensing agreements.

Executives

Joseph Truitt	director, officer: Chief Executive Officer	C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Kurt Graves	director	C/O ACHILLION PHARMACEUTICALS INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Michael D Kishbauch	director	18 CHERRYVILLE RD, FLEMINGTON NJ 08822
Jason S Fisherman	director	C/O ADVENT INTERNATIONAL CORP, 75 STATE ST 29TH FLOOR, BOSTON MA 02104
Van Nostrand Robert L	director	C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Nicole Vitullo	director	3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Martha E Manning	officer: General Counsel	700 PENNSYLVANIA DR, EXTON PA 19341
Frank Verwiel	director	C/O INTERMUNE, INC., 3280 BAYSHORE BLVD., BRISBANE CA 94005
Paul E Firuta	officer: EVP, Chief Commercial Officer	550 HILLS DRIVE, THIRD FLOOR, BEDMINSTER NJ 07921
Steven Zelenkofske	officer: EVP, Chief Medical Officer	120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920
Mary Kay Fenton	officer: Chief Financial Officer	ACHILLION PHARMACEUTICALS, 300 GEORGE STREET, NEW HAVEN CT 06511
Milind Deshpande	director, officer: Chief Executive Officer	ACHILLION PHARMACEUTICALS, 300 GEORGE STREET, NEW HAVEN CT 06511
Johnson & Johnson Innovation - Jjdc, Inc.	10 percent owner	410 GEORGE STREET, NEW BRUNSWICK NJ 08901
Johnson & Johnson	10 percent owner	ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ 08933
David Apelian	officer: Chief Medical Officer	C/O ACHILLION PHARMACEUTICALS, INC, 300 GEORGE STREET, NEW HAVEN CT 06511